# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-18
**æ›´æ–°æ—¶é—´**: 2026-01-18 13:24
**æ–°é—»æ•°é‡**: 32

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºFDAç›‘ç®¡æ”¿ç­–è°ƒæ•´ä¸é‡ç£…è¯ç‰©å¸‚åœºè¡¨ç°ã€‚FDAæ­£è€ƒè™‘è°ƒæ•´IæœŸä¸´åºŠè¯•éªŒè§„å®šä»¥åº”å¯¹ä¸­å›½ç”Ÿç‰©æŠ€æœ¯å‘å±•ï¼ŒåŒæ—¶åŠ é€Ÿå®¡æ‰¹ç¨‹åºé¢ä¸´ä¼ä¸šæ‹…å¿§ã€‚è¯ºå’Œè¯ºå¾·GLP-1å£æœè¯ä¸Šå¸‚é¦–å‘¨è¡¨ç°å¼ºåŠ²ï¼Œè€ŒEpkinlyåœ¨æ·‹å·´ç˜¤IIIæœŸè¯•éªŒä¸­æœªèƒ½æ”¹å–„æ€»ç”Ÿå­˜æœŸã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**1. Makary talks FDA's plans to combat China's biotech growth** â­â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAå±€é•¿æ˜ç¡®è¡¨æ€è°ƒæ•´IæœŸè¯•éªŒè§„å®šï¼Œç›´æ¥å›åº”ä¸­å›½ç”Ÿç‰©æŠ€æœ¯å´›èµ·ï¼Œå¯èƒ½é‡å¡‘å…¨çƒä¸´åºŠè¯•éªŒç«äº‰æ ¼å±€

**3. Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading** â­â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - è¯ºå’Œè¯ºå¾·GLP-1å£æœè¯ä¸Šå¸‚é¦–å‘¨å¤„æ–¹é‡è¶…3000ï¼Œæ˜¾ç¤ºå‡è‚¥è¯å¸‚åœºæŒç»­çˆ†å‘ï¼Œå£æœå‰‚å‹å¯èƒ½è¿›ä¸€æ­¥æ‰©å¤§å¸‚åœºæ¸—é€

**19. AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - Epkinlyåœ¨å¼¥æ¼«æ€§å¤§Bç»†èƒæ·‹å·´ç˜¤IIIæœŸè¯•éªŒä¸­æœªèƒ½æ”¹å–„æ€»ç”Ÿå­˜æœŸï¼Œå¯¹å·²ä¸Šå¸‚è¯ç‰©æ„æˆé‡å¤§ä¸´åºŠæ•°æ®æŒ‘æˆ˜

**6. FDA delays reviews for two drugs in new voucher program** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAæ¨è¿Ÿæ–°åŠ é€Ÿå®¡è¯„é¡¹ç›®ä¸­ä¸¤ä¸ªè¯ç‰©çš„å®¡æŸ¥ï¼Œåæ˜ ç›‘ç®¡ç¨‹åºè°ƒæ•´ä¸­çš„æ‰§è¡ŒæŒ‘æˆ˜

**24. Supreme Court will hear Hikmaâ€™s â€˜skinny labelâ€™ fight against Amarin** â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - æœ€é«˜æ³•é™¢å°†å®¡ç†"ç˜¦èº«æ ‡ç­¾"æ¡ˆï¼Œåˆ¤å†³ç»“æœå¯èƒ½é‡å¡‘ä»¿åˆ¶è¯å¸‚åœºå‡†å…¥è§„åˆ™

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ImmunityBioçš„ç°è´§å‹ç»†èƒç–—æ³•åœ¨ç½•è§è¡€ç™Œæ—©æœŸè¯•éªŒä¸­æ˜¾ç¤ºæ½œåŠ›ï¼›Agomabå’ŒSpyGlassæäº¤IPOç”³è¯·ï¼Œæ˜¾ç¤ºæŠ•èµ„è€…å¯¹ç”Ÿç‰©æŠ€æœ¯æ¿å—æŒç»­çƒ­æƒ…
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): Epkinlyåœ¨DLBCLçš„IIIæœŸè¯•éªŒä¸­æ€»ç”Ÿå­˜æœŸæ•°æ®æœªè¾¾ç»ˆç‚¹ï¼›FDAåŠ é€Ÿå®¡æ‰¹æ¸…å•æ›´æ–°æ˜¾ç¤ºéƒ¨åˆ†ç™Œç—‡è¯ç‰©å·²éªŒè¯ä¸´åºŠè·ç›Š

### ğŸ”® æ˜æ—¥å…³æ³¨

éœ€å…³æ³¨æœ€é«˜æ³•é™¢å¯¹"ç˜¦èº«æ ‡ç­¾"æ¡ˆçš„å®¡ç†è¿›å±•ã€FDAå¯¹IæœŸè¯•éªŒè§„å®šçš„å…·ä½“ä¿®æ”¹æ–¹æ¡ˆï¼Œä»¥åŠæ›´å¤šGLP-1å£æœè¯çš„å¸‚åœºè¡¨ç°æ•°æ®ã€‚åŒæ—¶åº”ç›‘æµ‹ä¸­å›½ç”Ÿç‰©æŠ€æœ¯å…¬å¸å¯¹FDAæ”¿ç­–å˜åŒ–çš„ååº”ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 9 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 18 |
| ç»¼åˆ (ç»¼åˆ) | 5 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ Makary talks FDA's plans to combat China's biotech growth

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 19:51
- **é‡è¦æ€§**: â­â­â­â­

> As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/makary-talks-fdas-plans-to-combat-chinas-biotech-growth/)

---

### ğŸ‡ºğŸ‡¸ Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-16 16:24
- **é‡è¦æ€§**: â­â­

> More than 3,000 prescriptions were written for Novo&rsquo;s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached a settlement over a trading scandal and Sanofi is reportedly circling an eye drug biotech.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wegovy-pill-sales-emergent-sanofi-ocular-jazz-novo/809709/)

---

### ğŸ‡ºğŸ‡¸ Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 22:05
- **é‡è¦æ€§**: â­â­

> SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening. The drug developers hope to build on the strong start set by Aktis Oncologyâ€™s $318 million Nasdaq listing last ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/)

---

### ğŸ‡ºğŸ‡¸ Drugmakers without MFN pacts are bracing to make one

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 20:48
- **é‡è¦æ€§**: â­â­

> All but 17 drugmakers avoided a direct demand from President Donald Trump last year to lower their prices significantly. But that likely wonâ€™t last. There was a subtle unease among executives of some of the ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/drugmakers-without-mfn-pacts-are-bracing-to-make-one/)

---

### ğŸ‡ºğŸ‡¸ AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 21:01
- **é‡è¦æ€§**: â­

> AbbVie and Genmabâ€™s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma. The Phase 3 trial enrolled patients who had received at least one prior therapy ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/)

---

### ğŸ‡ºğŸ‡¸ ImmunityBio's cell therapy posts encouraging early data in rare blood cancer

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 16:05
- **é‡è¦æ€§**: â­

> ImmunityBioâ€™s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma. The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with WaldenstrÃ¶m non ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/immunitybio-cell-therapy-posts-encouraging-early-data-in-rare-blood-cancer/)

---

### ğŸ‡ºğŸ‡¸ JPM recap; Mirador raises $250M; Genentechâ€™s PBM shift; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-17 11:00

> Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We wonâ€™t be sending newsletters on Monday, but weâ€™ll be back in your inbox on Tuesday. The Endpoints News ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/)

---

### ğŸ‡ºğŸ‡¸ Supreme Court will hear Hikmaâ€™s â€˜skinny labelâ€™ fight against Amarin

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 20:06

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/supreme-court-will-hear-hikmas-skinny-label-fight-against-amarin/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-16 14:42

> SAN FRANCISCO â€” Throughout his 53 meetings at this year's JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone's minds. "We're going to put a cup in the middle of ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Verified Clinical Benefit | Cancer Accelerated Approvals

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 15:17
- **é‡è¦æ€§**: â­â­â­

> This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals)

---

### ğŸ‡ºğŸ‡¸ Drug Safety Oversight Board

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:17
- **é‡è¦æ€§**: â­â­

> The DSB is composed of representatives from two FDA Centers and eight other federal government agencies, the Agency for Healthcare Research and Quality, Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Department of Defense.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/drug-safety-oversight-board)

---

### ğŸ‡ºğŸ‡¸ Patient Listening Session Summaries

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:13
- **é‡è¦æ€§**: â­â­

> Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/patients/fda-patient-listening-sessions/patient-listening-session-summaries)

---

### ğŸ‡ºğŸ‡¸ Resources for Biomarker Requestors

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 21:11
- **é‡è¦æ€§**: â­â­

> Information and resources for requestors about FDAâ€™s Biomarker Qualification Program

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/biomarker-qualification-program/resources-biomarker-requestors)

---

### ğŸ‡ºğŸ‡¸ Tips for Section 804 Importation Program Proposals (SIPs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 18:39
- **é‡è¦æ€§**: â­â­

> FDAâ€™s tips for section 804 state importation program (SIP) proposals provide information to assist states and tribes develop their proposals.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/tips-section-804-importation-program-proposals-sips)

---

### ğŸ‡ºğŸ‡¸ Section 804 Importation Program Policies and Authorizations

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:17
- **é‡è¦æ€§**: â­â­

> FDA has issued policies and taken actions to implement section 804 of the Federal Food, Drug and Cosmetic Act, which allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-policies-and-authorizations)

---

### ğŸ‡ºğŸ‡¸ Section 804 Importation Program (SIP) Proposals and FDAâ€™s Review Process

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:13
- **é‡è¦æ€§**: â­â­

> Section 804 of the Federal Food, Drug and Cosmetic Act allows states and Indian tribes to import certain prescription drugs from Canada to significantly reduce the cost of these drugs without imposing additional risk to public health and safety.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-sip-proposals-and-fdas-review-process)

---

### ğŸ‡ºğŸ‡¸ Importation Program under Section 804 of the FD&C Act

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:13
- **é‡è¦æ€§**: â­â­

> FDA has developed a pathway under section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) that allows states and Indian tribes to import certain prescription drugs from Canada. Learn more.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-imports/importation-program-under-section-804-fdc-act)

---

### ğŸ‡ºğŸ‡¸ FDA Authorizes Floridaâ€™s Drug Importation Program

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:04
- **é‡è¦æ€§**: â­â­

> FDA authorized Floridaâ€™s Agency for Health Care Administrationâ€™s Section 804 Importation Program (SIP) in accordance with section 804 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and the FDAâ€™s implementing regulations.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/news-events/press-announcements/fda-authorizes-floridas-drug-importation-program)

---

### ğŸ‡ºğŸ‡¸ State Importation Program Enhancements

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 16:54
- **é‡è¦æ€§**: â­â­

> FDA is committed to continuing to work with states and Indian tribes that seek to develop an importation proposal under section 804 of the Federal Food, Drug and Cosmetic Act.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/reports/state-importation-program-enhancements)

---

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 15:01
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ My Dog Has Cancer: What Do I Need to Know?

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 13:44
- **é‡è¦æ€§**: â­â­

> Just as FDA reviews drugs for humans for safety and effectiveness before they can go on the market, the agency does the same for treatments for animals. Learn how FDA brings new oncology treatments to market and questions to ask your vet about your dog's cancer diagnosis.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/consumers/consumer-updates/my-dog-has-cancer-what-do-i-need-know)

---

### ğŸ‡ºğŸ‡¸ Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted  under PREA from 2012 â€“ present

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 18:40
- **é‡è¦æ€§**: â­

> The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 23:19

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Section 804 Importation Program Quality Assurance Tool

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 17:14

> This quality assurance (QA) tool is designed to assist section 804 importation program (SIP) sponsors prepare proposals that fully comply with the requirements under the final rule.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/importation-program-under-section-804-fdc-act/section-804-importation-program-quality-assurance-tool)

---

### ğŸ‡ºğŸ‡¸ Human Drug Imports

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 16:53

> Human drug import information including PLAIR, safe importation action plan, and personal importation policy.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-imports)

---

### ğŸ‡ºğŸ‡¸ Recently Issued Guidance Documents

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 15:59

> This page lists Recently Issued CBER and Cross-Center Guidance Documents.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/vaccines-blood-biologics/biologics-guidances/recently-issued-guidance-documents)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-16 14:47

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ STAT+: FDA delays reviews for two drugs in new voucher program

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:36
- **é‡è¦æ€§**: â­â­

> And more biotech news, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/16/biotech-news-fda-delays-review-in-voucher-program/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about FDA voucher worries, weight loss drugs and jet fuel, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 14:30
- **é‡è¦æ€§**: â­â­

> Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines over possible legal risks

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/trump-fda-voucher-obesity-novo-lilly-covid/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ <a href="https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next" hreflang="en">After AbbVie and Genmab's ph. 3 survival miss for Epkinly in DLBCL, what's next?</a>

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-16 15:29

> Just days after AbbVie unveiled a major new oncology play in the form of its high-dollar RemeGen collab, the Illinois drugmaker closed out the week with some mixed news for marketed cancer offering Epkinly.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/after-abbvie-and-genmabs-ph-3-survival-miss-epkinly-dlbcl-whats-next)

---

### ğŸ‡ºğŸ‡¸ STAT+: Supreme Court agrees to review â€˜skinny labelingâ€™ and generic drug access

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 21:03

> The Supreme Court agreed to review a controversy over so-called skinny labels for medicines, a decision that will be closely watched for its implications for the availability of generic medicines.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/scotus-generics-patents-supreme-court-amarin-hikma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-16 17:00

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/16/pharma-biotech-jobs-novo-bristol-astrazeneca/?utm_campaign=rss)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-18 13:24:37*